BioHarvest Sciences Inc appoints pharmaceutical industry veteran Dr George Garibaldi to its Scientific Board of Advisors
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) said it has appointed Dr George Garibaldi, who has more than 40 years of experience in drug development and the pharmaceutical industry, to its Scientific Board of Advisors.
Dr Garibaldi is the co-founder and president of research and development of Noema Pharma AG and he has previously held leadership responsibilities at several major pharmaceutical companies, more recently serving as VP and Global Head of Clinical Neuroscience at F Hoffmann-La Roche, BioHarvest said.
BioHarvest CEO Ilan Sobel noted that Garibaldi’s extensive experience in the pharmaceutical industry was a great addition to the company’s Scientific Board of Advisors.
READ: BioHarvest Sciences CEO projects 3-3.5x revenue growth next year in 2022 shareholder letter
“Understanding the entire development cycle of drugs is critical for the company’s ability to serve this high-priority segment of our business. George’s expertise and involvement will play an important role in solidifying our plant-based biotech leadership,” Sobel said in a statement.
Dr Garibaldi stated that he was joining BioHarvest’s Scientific Board of Advisors because he believes in the potential of its biotech platform.
“The company has proven its ability to industrially produce unique, patentable and consistent compositions of phytochemicals such as polyphenols and cannabinoids. The medical field has consistently highlighted the therapeutic potential of these products. Together with the community of health care providers, we will explore opportunities to develop therapies addressing a plethora of health conditions,” Dr Garibaldi added.
BioHarvest Sciences is a Canadian-listed biotechnology firm that has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants at an industrial scale without the need to grow the plant itself.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie
No Byline Policy
Editorial Guidelines
Corrections Policy
Source